October 10: The Week in Cancer News
Older people with multiple myeloma can receive a less toxic drug regimen, and the FDA approves an immunotherapy for people with high-risk skin cancer.
Progress Against Cancer
Older people with multiple myeloma can receive a less toxic drug regimen, and the FDA approves an immunotherapy for people with high-risk skin cancer.
The FDA approved cemiplimab-rwlc as an adjuvant therapy for patients with cutaneous squamous cell carcinoma at high risk of recurrence. The U.S. Food and Drug Administration (FDA) has approved cemiplimab-rwlc (Libtayo) for use after...
Patients with cancer in rural or high-poverty areas were associated with the most significant improvements in five-year survival. In 2014, a provision under the Patient Protection and Affordable Care Act (ACA) took effect, allowing...
Widespread uptake of HPV vaccine linked to reduced rates of cancer-causing infection in all, and radiation prevents recurrence in locally advanced bladder cancer.
The FDA has approved the DNA-damaging agent in combination with immunotherapy for patients whose cancers have not progressed after first-line therapy. The U.S. Food and Drug Administration (FDA) has approved lurbinectedin (Zepzelca) in combination...
For September 2025, the editors of AACR's journals highlighted studies on cervical cancer screening, supercharging immunotherapy, and more.
US trial to look at impact of AI-assisted mammograms, and vitamin B12 may help curb chemotherapy-associated hand-foot syndrome.
The FDA has approved imlunestrant for certain patients with advanced ESR1-mutated breast cancer that has progressed following previous endocrine therapy. The U.S. Food and Drug Administration (FDA) has approved imlunestrant (Inluriyo) for the treatment...
Richard and Michelle Schlueter attended the Rally for Medical Research to advocate for NIH funding after budget cuts delayed his treatment.
The FDA approved pembrolizumab and berahyaluronidase alfa-pmph as an injectable therapy for multiple tumor types. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex) for subcutaneous (under the...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More